Research and Markets: SUDA's SUD-001 (Migraine) Report - US Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7jxm2v/sud001) has announced the addition of the "SUD-001 (Migraine) - Forecast and Market Analysis to 2023" report to their offering.

SUDA is developing SUD-001 (previously known as NVD-201 by NovaDel) for the treatment of migraine headaches. The active drug in SUD-001 is GlaxoSmithKline's sumatriptan succinate (Imitrex) which is available in injection, tablet or nasal spray form. SUD-001, in contrast, is administered as an oral spray, which is based on SUDA's acquisition of NovaDel's NovaMist technology. The technology delivers liquid formulations of pharmaceutical product to the oral cavity in the form of a mist that covers the oral mucosal membranes.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Migraine

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of SUD-001 performance

- Obtain sales forecast for SUD-001 from 2012-2023 in the US.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

  • Etiology
  • Pathophysiology
  • Prognosis

3.2 Symptoms

  • Premonitory Phase
  • Aura Phase
  • Headache Phase
  • Postdrome Phase

4 Disease Management

  • Acute Migraine Treatment
  • Preventive Migraine Treatment

5 Competitive Assessment

6 Opportunity and Unmet Need

6.1 Overview

  • A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
  • Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
  • Lack of Diagnostic Tools Causes Misdiagnosis
  • Physician Education
  • Effective and Well-Tolerated Prophylactic Therapies

6.2 Unmet Needs Gap Analysis

  • Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
  • Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
  • Physician Education
  • Diagnostic Tools

7 Pipeline Assessment

8 SUD-001

  • Overview
  • Efficacy
  • Safety
  • Dosing and Formulation
  • Potential Clinical Positioning
  • Potential Commercial Positioning
  • Pricing and Reimbursement
  • SWOT Analysis
  • Forecast

9 Appendix

For more information visit http://www.researchandmarkets.com/research/7jxm2v/sud001

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System